Wanjiku, who competed here in the Rio 2016 Paralympic men’s under 59 kilograms competition on Friday (September 9), returned an adverse analytical finding for terbutaline in a urine sample provided on July 29 after an out-of-competition test in Kenya’s capital Nairobi.

The substance is included on the 2016 World Anti-Doping Agency (WADA) Prohibited List under the category “S3 Beta-2 Agonists” and is prohibited at all times, both in and out of competition, as a specified substance.

The IPC hearing body was said to be satisfied with Wanjiku’s account that the substance had entered his system after he had taken a single dose of cough medicine for clinical reasons.

The hearing body accepted the use was not linked to any sport related intention and therefore the athlete received a reprimand based on "no significant fault or negligence for a specified substance".

Powerlifting has long provided serious concern for the IPC and the sport has been plagued with doping cases.

Last month, Turkey’s Izzettin Kanat was suspended for two years for an anti-doping rule violation, meaning he would miss Rio 2016. 

Kanat returned an adverse analytical finding for meldonium in a urine sample provided on February 17, after he had competed in the men’s up to 80kg class at the seventh IPC Powerlifting World Cup in Dubai.

The heart attack drug has been included on the WADA Prohibited List since January 1, but has been the subject of much controversy due to question marks on how long it stays in the body.

A string of athletes have failed for meldonium since January 1, with the most profile being Russia's tennis superstar Maria Sharapova who was banned for two years.

A number of others had their bans either lifted or temporarily put on hold due to the confusion over the substance.